var data={"title":"Ioversol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ioversol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6394?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ioversol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ioversol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9520848\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Not for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184022\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Optiray 160 [DSC];</li>\n      <li>Optiray 240;</li>\n      <li>Optiray 300;</li>\n      <li>Optiray 320;</li>\n      <li>Optiray 350</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15793706\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Optiray 240;</li>\n      <li>Optiray 300;</li>\n      <li>Optiray 320;</li>\n      <li>Optiray 350</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184025\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524681\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dosing is based on numerous variables including: Type of examination, route of administration, patient age/weight and product; consult specific product information for detailed dosing information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524680\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524682\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962287\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use caution in severe impairment, anuria, and in setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962288\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184013\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Optiray 160: 34% (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Optiray 240: 51% (50 mL, 100 mL, 125 mL, 150 mL [DSC], 200 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Optiray 300: 64% (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Optiray 320: 68% (20 mL, 30 mL, 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Optiray 350: 74% (50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 250 mL, 500 mL) [contains edetate calcium disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184009\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524683\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hydrate well prior to and following administration. Premedication with antihistamines or corticosteroids may be considered in some patients to minimize the potential for allergic reactions. Intravenous doses should be at or close to body temperature prior to administration.  In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guidewire manipulation. When administering large doses (eg, aortography, ventriculography), several minutes should elapse between each injection to allow for subsidence of possible hemodynamic disturbances. <b>Not for intrathecal use.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara, 1983; Zenk, 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184014\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioversol 74%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Peripheral and coronary arteriography and left ventriculography; contrast-enhanced, computed, tomographic imaging of the head and body; IV excretory urography; IV digital subtraction angiography and venography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Angiocardiography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioversol 68%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Angiography throughout the cardiovascular system, including cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography; contrast-enhanced, computed, tomographic imaging of the head and body; IV excretory urography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Angiocardiography; contrast-enhanced, computed, tomographic imaging of the head and body; IV excretory urography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioversol 64%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Cerebral angiography and peripheral arteriography; contrast-enhanced, computed, tomographic imaging of the head and body; venography; IV excretory urography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioversol 51%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Cerebral angiography and venography; contrast-enhanced, computed, tomographic imaging of the head and body; IV excretory urography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174553\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9521836\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, cardiac complications (including cardiac output, left ventricular systolic and end-diastolic pressure, right ventricular systolic and pulmonary artery systolic pressures, decreases in systolic and diastolic blood pressures)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Disorientation (cerebral arteriography: &gt;1%; other procedures: &lt;1%), headache (cerebral arteriography: &gt;1%; other procedures: &lt;1%), vertigo (cerebral arteriography: &gt;1%; other procedures: &lt;1%), drowsiness, paresis (transient), seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acidosis, acute generalized exanthematous pustulosis, acute renal failure, anaphylactic shock, anaphylactoid reaction (with multiorgan failure), anaphylaxis, angina pectoris, anxiety, aphasia, atrioventricular block, back pain, blurred vision, cardiac arrhythmia, cardiac disease, cerebral infarction, chest pain, chills, complete atrioventricular block, conjunctivitis, coronary artery vasospasm, cortical blindness (transient), cough, dizziness, dysgeusia, dysphagia, dyspnea, erythema, erythema multiforme, facial edema, fatigue, flushing, hallucination, hyperhidrosis, hypersensitivity reaction, hypertension, hyperventilation, hypotension, hypothyroidism (transient; neonates), hypoxia, injection site reaction (including bruising, erythema, extravasation, hematoma, induration, nerve injury, pain, pruritus, skin rash), laryngeal edema, malaise, muscle spasm, myasthenia, myocardial infarction, nasal congestion, nodal arrhythmia, palpitations, paresthesia, periorbital edema, polyuria, presyncope, pruritus, pseudoaneurysm (vascular), pulmonary edema, renal pain, rhinitis, sneezing, skin rash, swelling, tinnitus, tremor, urinary retention, urticaria, vasodilation, vasospasm, vomiting, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184016\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to ioversol or any component of the formulation; clinically significant impairment of both hepatic and renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9520849\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Adverse reactions (including delayed reactions) have occurred, including serious and life-threatening reactions. Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever or food allergies). Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered to reduce incidence and severity of reaction. Monitor closely for 30 to 60 minutes after administration. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast-associated nephropathy: May occur. Use caution in patients with significant underlying renal impairment and/or concurrent renal and hepatic impairment, especially when large doses are required. Patients should be well hydrated before and after examination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to ioversol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Infiltration may result in tissue necrosis, particularly in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Serious neurologic events including permanent paralysis can occur following cerebral arteriography, selective spinal arteriography, and arteriography of blood vessels supplying the spinal cord. Cause and effect has not been established as underlying disease and procedural techniques may contribute; avoid arterial injection of contrast medium after vasopressor administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Caution in patients with history of epilepsy; focal and generalized motor seizures have been reported when higher than recommended doses used; antiepileptic therapy should be continued. Prophylactic anticonvulsant therapy should be considered in patients requiring a concentrated solution or large bolus of contrast media. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAOIs, tricyclic antidepressants, SSRIs), should be discontinued 24 to 72 hours prior to intrathecal use and not resumed for 24 hours post procedure (ACR, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing MI and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting may occur when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in severe cardiovascular disease and HF; transitory increase in circulatory osmotic load could occur. Observe patients with HF for several hours following the procedure to detect delayed hemodynamic disturbances which may be associated with a transitory increase in the circulating osmotic load. Perform selective coronary angiography only if the anticipated benefit outweighs potential risks. Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with combined renal and hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in multiple myeloma; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration. Partial dehydration in preparation for procedures may precipitate myeloma protein in renal tubules and is not recommended in myeloma patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used and closely monitor blood pressure throughout procedure. Therapy for treatment of hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: The inherent risks of angiocardiography in patients with chronic pulmonary emphysema must be weighed against the necessity for performing this procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal disease, combined renal and hepatic disease or anuria. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in diabetics, elderly, advanced vascular disease, and those who are dehydrated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in homozygous sickle cell patients; administration of contrast media may result in sickling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Pediatric patients at higher risk of experiencing adverse events during contrast medium administration may include those having asthma, sensitivity to medication or allergens, heart failure, serum creatinine &gt;1.5 mg/dL, or those &lt;12 months of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:<b> [US Boxed Warning]: Not for intrathecal use.</b> Inadvertent administration of iodinated contrast media that is not indicated for intrathecal use has resulted in serious adverse events, including death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls exists. Ensure proper catheter placement with test injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299535\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221113\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8964&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184011\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184018\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Ioversol crosses the placenta and can be detected in the newborn gut at birth (Hill 2007; Saigal 2007). In general, iodinated contrast media should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184019\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant&rsquo;s GI tract, breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breast-feeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015). The manufacturer recommends that caution be used if administered to a breast-feeding woman and that consideration be given to temporarily discontinuing breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29888467\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, vital signs (coronary arteriography and left ventriculography); signs and symptoms of hypersensitivity for &ge;30 to 60 minutes; renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524674\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524676\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.5 hours; prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine: &gt;95% eliminated unchanged in urine 24 hours postadministration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323209\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Optiray 240 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">51% (50 mL): $55.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Optiray 300 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">64% (50 mL): $47.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Optiray 320 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">68% (50 mL): $52.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Optiray 350 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">74% (50 mL): $57.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038661\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Optiject (FR, LU);</li>\n      <li>Optiray (AE, AR, AT, AU, BE, BG, CH, CO, CZ, DK, ES, GB, GR, HN, HR, IE, IT, JP, KR, KW, LK, MT, NL, NO, NZ, PE, PL, PT, PY, QA, RO, SE, SG, SI, SK);</li>\n      <li>Optirey (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. http://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, Practice guideline for the performance of myelography and cisternography. http://www.asnr.org/sites/default/files/guidelines/Myelography.pdf Updated 2008. Accessed September 1, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill BJ, Saigal G, Patel S, Abdenour GE Jr. Transplacental passage of non-ionic contrast agents resulting in fetal bowel opacification: a mimic of pneumoperitoneum in the newborn. <i>Pediatr Radiol</i>. 2007;37(4):396-398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/17323055/pubmed\" target=\"_blank\" id=\"17323055\">17323055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Optiray 350, Optiray 320, Optiray 300, Optiray 240 (ioversol injection) [prescribing information]. Raleigh, NC: Liebel-Flarsheim Company; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Optiray 240, 300, 320, 350 (ioversol injection) [product monograph]. Pointe-Claire, Quebec, Canada: Liebel-Flarsheim Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-2102.e3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saigal G, Abdenour GE. Another case of transplacental passage of the non-ionic contrast agent ioversol. <i>Pediatr Radiol</i>. 2007;37(7):726-727.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioversol-drug-information/abstract-text/17476497/pubmed\" target=\"_blank\" id=\"17476497\">17476497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8964 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9520848\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184022\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F15793706\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F184025\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9524681\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9524680\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9524682\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962287\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962288\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184013\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F184009\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9524683\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F184014\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174553\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9521836\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184016\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9520849\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299535\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221113\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184011\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184018\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F184019\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F29888467\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9524674\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9524676\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323209\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038661\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8964|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ioversol-patient-drug-information\" class=\"drug drug_patient\">Ioversol: Patient drug information</a></li></ul></div></div>","javascript":null}